Abstract of notice (in Italian) of Shareholders' agreement between AGC and Fininvest pursuant Art 122 Decree 58/98 (Consolidated Law on Finance) and Art. 129, comma 1 Issuers Regulation ("Regolamento Emittenti" n. 11971 May, 14 1999)
Lombardy Region approved the "agreement for innovation" scheme for the financing, together with the Ministry of Economic Development, of MolMed’s project proposal "New CAR therapies for the treatment of cancer patients"
Results from a new study on CAR T CD44v6 in in-vivo experimental models of lung carcinoma and melanoma confirm the high therapeutic potential of MolMed’s therapy also in solid tumors. The results have been presented today at the ESGCT
MolMed participates at the first annual meeting of the International Academy for Clinical Hematology ("IACH"). The therapeutic potential of Zalmoxis® in haploidentical transplantation and of CAR T CD44v6 in blood tumours presented at the summit.
Carlo Incerti succeeds to Claudio Bordignon as Chairman of the Board. The BoD calls Shareholders’ Meeting to resolve on capital increase, within the limit of 10%, with the exclusion of the option rights.
MolMed Board of Directors exercises the power to carry out the capital increase to be reserved to Société Générale of up to no. 42,000,000 ordinary shares pursuant to the agreement named “SEF - Standby Equity Facility”
MolMed Board of Directors exercises the power to carry out the capital increase to be reserved to Société Générale of up to no. 46,000,000 ordinary shares pursuant to the agreement named “SEF - Standby Equity Facility”